Monolith-based Pseudo-bioaffinity Purification Methods for Factor VIII from Various Sources and Applications Thereof
The Novel Technology:
The novel technology relates to the purification of Factor VIII protein and/or its fragments from various sources by employing various pseudobioaffinity based purification methods (Histidine Ligand Affinity Chromatography –HLAC coupled with monolith-based Convective Interaction Media – CIM).
Applications:
- To use for the purification of:
- native factor VIII from plasma cryoprecipitate,
- recombinant B-domain deleted factor VIII:C expressed in various host systems,
- recombinant factor VIII mutant having improved activity and stability, and
- recombinant FVIII expressed in Pichia pastoris
Advantages:
- No column packing or clogging problem
- Flow independent specific binding
- Mild elusion avoids any denaturation process of the target protein
- Minimal processing time and high throughput steps in comparison to classical affinity-based purification techniques to recover Factor VIII:C
- Purified without any significant loss of activity
- Increase in recovery yield and increase in purity
Business Model:
The technology is in early stage of development. Looking for potential licensee(s) interested in taking the technology to next step of development. There is a possibility of getting FDA approval and supply of chromatographic system by the producer.
Principal Investigator(s): Prof. M. A. Vijiyalakhsmi, CBST
Invention ID: CMP-029
IP status: Patent Pending
Jurisdictions: India (IN), United States (US), Europe (EP)
For more details, please write to:
techtransfer @ ccamp.res.in